Trial Profile
A Randomized Open-label Phase II Study of Oral Dovitinib in Combination With Androgen Deprivation Therapy to Delay the Onset of Castration-resistant Disease in Patients With Metastatic Prostate Cancer Undergoing Primary Androgen Deprivation Therapy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Dovitinib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 18 Jan 2015 Status changed from not yet recruiting to withdrawn prior to enrolment, as reported by ClinicalTrials.gov.
- 25 Apr 2014 Planned End Date changed from 1 Feb 2018 to 1 May 2018 as reported by ClinicalTrials.gov.
- 25 Apr 2014 Planned initiation date changed from 1 Feb 2014 to 1 May 2014 as reported by ClinicalTrials.gov.